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Abstract: A marked decrease in human cancers, including breast cancer, bone cancer, and cervical
cancer, has been linked to the consumption of vegetable and fruit, and the corresponding
chemoprotective effect has been associated with the presence of several active molecules, such
as kaempferol. Kaempferol is a major flavonoid aglycone found in many natural products, such
as beans, bee pollen, broccoli, cabbage, capers, cauliflower, chia seeds, chives, cumin, moringa
leaves, endive, fennel, and garlic. Kaempferol displays several pharmacological properties, among
them antimicrobial, anti-inflammatory, antioxidant, antitumor, cardioprotective, neuroprotective,
and antidiabetic activities, and is being applied in cancer chemotherapy. Specifically, kaempferol-rich
food has been linked to a decrease in the risk of developing some types of cancers, including skin,
liver, and colon. The mechanisms of action include apoptosis, cell cycle arrest at the G2/M phase,
downregulation of epithelial-mesenchymal transition (EMT)-related markers, and phosphoinositide
3-kinase/protein kinase B signaling pathways. In this sense, this article reviews data from experimental
studies that investigated the links between kaempferol and kaempferol-rich food intake and cancer
prevention. Even though growing evidence supports the use of kaempferol for cancer prevention,
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further preclinical and clinical investigations using kaempferol or kaempferol-rich foods are of pivotal
importance before any public health recommendation or formulation using kaempferol.
Keywords: kaempferol; pharmacokinetics; pharmacodynamics; antioxidant; anticancer;
chemoprevention; apoptosis; cell cycle arrest; metastasis; reactive oxygen species
1. Introduction
Kaempferol represents one of the most encountered aglycone flavonoids in the form of glycoside.
It is a tetrahydroxyflavone in which the four hydroxy groups are located at positions 3, 5, 7, and 4′,
and it is a yellow compound [1]. Kaempferol is found in various plant parts, such as seeds, leaves, fruits,
flowers, and even vegetables [2–4]. Kaempferol and its glycosylated derivatives have been shown
to be cardioprotective, neuroprotective, anti-inflammatory, antidiabetic, antioxidant, antimicrobial,
antitumor, and have anticancer activities [5].
Epidemiological studies showed that a high intake of kaempferol is associated with decreased
incidence of different types of cancer, among which cancer in organs like skin, liver, colon, ovary,
pancreas, stomach, and bladder [6,7]. In this context, kaempferol consumption and related application in
cancer therapy are gaining huge attention among the research community [6–8]. The cancer prevention
is mostly achieved by inhibiting the proliferation of cancer cells through increasing the apoptosis [9–11].
Indeed, kaempferol inhibits various cancer cells by triggering apoptosis, cell cycle arrest at G2/M phase,
downregulation of signaling pathways and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT),
expression of epithelial-mesenchymal transition (EMT)-related markers (N-cadherin, E-cadherin, Snail,
and Slug), and matrix metallopeptidase 2 (MMP-2), metastasis-related markers [12,13]. Kaempferol also
induces the activation of cysteine proteases involved in apoptosis initiation and execution, caspases-3,
-7, -9, and Poly (ADP-ribose) polymerase (PARP) [14], therefore preventing the accumulation of
reactive oxygen species (ROS) involved in cancer development [15]. The inhibition of angiogenesis
was also reported as well as the capacity of kaempferol to preserve normal cell viability [15]. In this
context, this review summarizes data on pharmacodynamics, chemopreventive and anticancer effects,
and mechanisms of action of kaempferol.
2. Metabolism and Pharmacokinetics of Kaempferol
Studies on the in vitro and in vivo pharmacokinetics of kaempferol commonly ingested as high
polarity glycosides revealed that this polyphenol is poorly absorbed compared to the aglycones with
intermediate polarity [16].
Kaempferol lipophilicity allowed its absorption in the small intestine through passive and facilitated
diffusion or active transport [17]. Of note, intake of 14.97 mg kaempferol/day and 27 mg kaempferol from
tea resulted in a plasma concentration of 16.69 ng/mL and 15 ng/mL, respectively [18]. The absorbed
kaempferol undergoes metabolic transformation to yield the glucuronides and sulfoconjugates forms in
the liver [19] and small intestine by intestinal conjugation enzymes [17]. As well, kaempferol
and its glycosides are metabolized in the colon by the bacterial microflora that releases the
aglycones and broke aglycone C3 ring to form compounds such as 4-methylphenol, phloroglucinol,
and 4-hydroxyphenylacetic acid, that are either absorbed and can reach systemic circulation and
tissues or be excreted in feces and urine [20–27]. To overcome the low bioavailability of kaempferol,
its combination with quercetin increase its bioavailability, consequently improving its bio-efficacy.
In fact, studies prove that nanoformulations (e.g., nanoparticles, nanoemulsions, nanoencapsulation)
containing kaempferol will be extremely beneficial in improving their bioavailability and consequent
efficacy and selectivity for mutated cells, while their effect on normal cells will be limited [28]. Indeed,
kaempferol exerts protective effects in non-mutated cells, whereas it triggers apoptosis in those mutated
ones. These aspects are mostly linked to the remarkable antioxidant effects of kaempferol, namely acting
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directly in antioxidant enzymes, capable of efficiently inhibit ROS generation and lipid peroxidation,
and, finally, preventing the occurrence of cell damages, in a broad-spectrum activity [29].
3. Antioxidant Potential of Kaempferol
Kaempferol and its glycosides, as well as kaempferol-containing plants, portray antioxidant
potency both in culture and in animal models [26,27], and it has the capacity to decrease the production
of free radicals and other products like reactive oxygen species (ROS). ROS are aerobic metabolism
by-products that can induce malignant cell transformation. Thereafter, ROS production inhibition
can reverse malignant cancer cell phenotype [28–31]. Usually, superoxide anion is either converted
by superoxide dismutase into H2O2 that react with reduced metals (e.g., ferrous or cuprous ions),
to yield the highly reactive hydroxyl radical or form peroxynitrite by reacting with nitric oxide.
These two highly reactive species, hydroxyl radical and peroxynitrite, can cause lipids, proteins,
or DNA damages [32]. At submicromolar concentrations, kaempferol is not only a potent scavenger of
superoxide anion, hydroxyl radical, and peroxynitrite [32–34], but it also inhibits pro-oxidant enzymes,
such as xanthine oxidase [35], and activates antioxidant enzymes such as superoxide dismutase,
catalase, and heme oxygenase-1 (Figure 1) [36,37] and even prevents the generation of hydroxyl radical
by chelating cuprous or ferrous [38,39]. Also, and not least important to highlight, is that kaempferol
contains hydroxyl groups at C3, C5, and C4, an oxo group at C4, and a double bond at C2-C3 that
might explain its antioxidant activity [32].
Conclusively, kaempferol can control the cancer through its antioxidative/antinitrosative and
anti-inflammatory potential by restoring the cell redox hemostasis by inhibiting the NF-κB pathway
and to up-regulate the Nrf2 transcriptional pathway (Figure 1).
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Figure 1. Antioxidant mechanisms of action of kaempferol: The kaempferol reduces the ROS
metabolism, cleavage of anti-inflammatory membranes, and disrupts their molecular mechanism as
a mechanistic concern to tackle cancer-related expressions (KMF: Kaempferol; Nrf2: Nuclear factor
erythroid 2-related factor 2; Keap1: Kelch-like ECH-associated protein 1; RO: Reactive oxygen species).
4. Anticancer Properties of Kaempferol
4.1. Anti-Breast Cancer Activity
Breast cancer burden has been increasing over the years and it represents the most-encountered
cancer in women [40]. At micromolar concentrations, kaempferol effectively inhibits the growth of breast
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cancer cell lines (VM7Luc4E2, MDA- MB-231, MCF-7) [40–43]. Also, kaempferol markedly inhibits
the bisphenol A (BPA) (endocrine-disrupting chemicals) and triclosan (TCS)-induced anti-apoptotic
processes [44], causes cell arrest at the G2/M stage, and even induces apoptosis and DNA fragmentation
at the sub-G0 phase (Table 1). Kaempherol increases the levels of pro-apoptotic enzymes and proteins,
such as cleaved caspase-9, -7, -3, p21, p53, Bax, PARP, and p-ATM [45,46] and decreased the levels
of anti-apoptotic proteins Bcl2, polo-like kinase 1 (PLK-1), pAKT, phosphorylated insulin receptor
substrate 1 (pIRS-1), phosphorylated mitogen-activated protein kinase (pMEK)1/2, cyclin-dependent
kinase 1 (CDK1), cyclins A, B, D1, and E, and cathepsin D [10,40,41,45–49]. In triple-negative breast
cancer cells (TNBC), kaempferol decrease cell migration and invasion stages when compared to
non-TNBC cells (control) [42]. This is explained by the downregulation of RhoA and activation of Rac1
in TNBC cells, as well as through activation of human epidermal growth factor receptor-2 (HER2)-silence
SK-BR-3 and ER/PR-silence in non-TNBC cells [42], which suggests that the antiproliferative action
of kaempferol is triggered via the ER-dependent pathway that mediates cellular processes including
development, differentiation, and proliferation [50]. In addition, kaempferol significantly activates
mitogen-activated protein kinase (MAPK) cascades, which are key signaling pathways involved in
the regulation of normal cell proliferation, survival, and differentiation. Indeed, kaempferol activates
extracellular signal-regulated kinase (ERK), concomitantly with MEK1 and ELK1; while it reduces
EMT and metastasis. The MAPK signaling pathway, when activated, leads to the transcription
factor activator protein-1 (AP-1), cathepsin B and D, MMP-2 and -9 activation, that consequently
reduces cell adhesion, migration, and invasion [51–54]. Also, kaempferol also lowers the glucose
transporter 1 (GLUT1) mRNA levels and prevents the uptake of (3)H-deoxy-d-glucose ((3)H-DG)
and monocarboxylate transporter 1 (MCT1)-mediated lactate cellular leading to extracellular lactate
accumulation (Figure 2) [40].Molecules 2019, 24, x 5 of 18 
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4.2. Anti-Brain Cancer Activity
Glioblastoma is one of the most invasive and aggressive brain tumors, with a very poor prognosis,
among other reasons, secondary to the development of resistance against current therapies [55]. It has been
reported that Kaempferol inhibited both growth and migration of glioma cells, even when kaempferol
was loaded to mucoadhesive nanoemulsion (KPF-MNE) or kaempferol-loaded nanoemulsion
(KPF-NE) [55–57]. This flavonoid also triggers ROS generation and apoptosis, through reduction
of the thioredoxin concentrations, superoxide dismutase activity, as well as to increase the levels
of pro-inflammatory cytokines (interleukin-6, 8, chemokines, monocyte chemo-attractant protein-1),
Bcl-2, cleaved caspase-3, -8, anti-apoptotic proteins survivin and XIAP, cleaved poly(ADP-ribose)
polymerase expression, depolarization of mitochondrial membrane potential, and rapid reduction in
phosphorylation of ERK and AKT [55,56,58].
4.3. Anti-Liver Cancer Activity
Hepatocellular carcinoma (HCC) is the most-encountered primary liver cancer among adults [59].
Kaempferol was revealed to significantly inhibit, in a dose-dependent manner, human hepatic
cancer cells proliferation (HepG2, SK-HEP-1, Huh7). In addition, diethylnitrosamine and
2-acetylaminofluorene-induced HCC from rats treated with kaempferol combined to luteolin inhibited
cell growth and induced cell death [60,61]. Indeed, kaempferol induces cell apoptosis and causes
cell cycle arrest at the G2/M phase, therefore preventing cell migration and invasion. Kaempferol is
also able to release cytochrome c via ROS generation triggering mitochondrial membrane potential
loss and mitochondrial swelling and increasing the level of cleaved caspase-3 [59–61]. Kaempferol
also decreases the expression level of miR-21, cytokine signaling 3 (SOCS3), signal transducer and
activator of transcription 3 (STAT3), CDK1, cyclin B, PI3K/AKT/mTOR and p-mTOR signaling pathway,
and hypoxia-inducible factor 1 (HIF-1) in human hepatic cancer cells and enhanced the expression of
Janus kinase 1 (JAK1), tyrosine kinase 2 (Tyk2), STAT1/2, endogenous interferon (IFN)-α-regulated
genes, phosphatase and tensin homologue (PTEN), microtubule-associated protein 1A/1B-light chain 3
(LC3-II), p44/42 MAPK, beclin 1, and autophagy-related gene (Atg) 5, 7, and 12 [60–63].
4.4. Anti-Colon Cancer Activity
Colorectal cancer is amongst the most frequently found cancers worldwide, with more than
1.8 million new cases per year [64]. Kaempferol was reported to possess cytotoxic effects on different
human colorectal cancer cells lines, including HCT116, HT-29, HCT-15, LS174-R colon, and SW480
cells [64–66].
Even though 5-Fluorouracil is subjected to therapeutic failure due to resistance development, it
is still the most recommended chemotherapeutic agent. Experimental studies combined kaempferol
with 5-Fluorouracil in LS174-R cells and reported interesting antiproliferative effects [64]. In addition,
kaempferol in combination with tumor necrosis factor ligand superfamily member (TRAIL) led to
apoptosis in colon cancer cells, through up-regulation of TRAIL receptors and death receptor 5 (DR5)
that improved the TRAIL activity [67]. Generally, kaempferol induces apoptosis and cell cycle arrest at
G2/M, and reduces both cell migration and invasion [64,66]. Kaempferol also blocked ROS production
and modulated the expression of MAPK, JAK/STAT3, PI3K/AKT, ATM, H2A histone family member
X (H2AX), phospho-p38, p21, p53, PARP, caspase-3, -7, -8, -9, Bcl-2, p53 upregulated modulator of
apoptosis (PUMA), the release of cytochrome c from mitochondria, connexin 43, ERK-1/2, and nuclear
factor kappa B (NF-κB). Also, kaempferol significantly reduced insulin-like growth factor (IGF)-II
secretion, and heregulin (HRG)-β, CDK2, CDK4, Cdc25C, Cdc2, cyclins B1, D1, E, A, and connexin
43 expressions. Finally, it also suppressed the phosphorylation of retinoblastoma protein and enhanced
the PARP cleavages [64–66,68–71].
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4.5. Anti-Prostate Cancer Activity
Prostate cancer is one of the leading causes of death among man and the need for more
effective treatments has driven further research [72]. Kaempferol-3-O-rhamnoside dose-dependently
inhibits prostate cancer cells proliferation [72], by upregulating the expression of caspase-8, -9, -3,
and poly (ADP-ribose) polymerase proteins [72,73]. Granulocyte-macrophage colony-stimulating
factor (GM-CSF) is known to activate the host immune system and to facilitate host immunosurveillance
by the dendritic cells (DC), thereby representing a promising strategy to thwart prostate cancer [73].
Kaempferol has been shown to induce GM-CSF release in PC-3 cells that, in turn, increase the
chemotaxis of DC through activation of phospholipase C (PLC), MEK1/2, and protein kinase C
(PKC) [73]. Obviously, the transcriptome of prostate cancers cells is also markedly affected by
kaempferol treatment as evidenced by the down-regulation of androgen receptor genes expression [74].
In rats, orally administered kaempferol showed no significant toxicity and significantly increased
survival, in addition to reducing the growth of PCa xenografts in athymic nude mice [74].
4.6. Anti-Pancreatic Cancer Activity
Pancreatic cancer is amongst the most common cancer-related causes of deaths worldwide with
the nastiest prognosis [75]. Kaempferol dose-dependently inhibits the growth of pancreatic cancer
cells, SNU-213, Panic-1, and Miapaca-2, through inducing apoptosis [75] and effectively inhibiting
cell migration, ERK1/2, epidermal growth factor receptor (EGFR)-related Src, and AKT pathways [76].
Kaempferol also improves the suppressive activity of regulatory T cells (Tregs) by increasing the FOXP3
expression level [77,78].
4.7. Anti-Blood Cancer Activity
Acute promyelocytic leukemia is a life-threatening blood cancer, characterized by a defect in
cell growth and apoptotic pathways [79]. Kaempferol (12.5–100µM) dose-dependently decreased
cell viability in human leukemia cells, HL-60 and NB4 [79,80]. Kaempferol also promoted apoptosis,
cell cycle arrest at the G2-M phase, and DNA damages [79–84], and down-regulated the expression
of AKT, ABCB1, BCL2, and ABCC1 genes, protein expression associated with DNA repair system,
as well as DNA-dependent serine/threonine protein kinase (DNA-PK), phosphate-ataxia-telangiectasia
and Rad3-related (p-ATR), phosphate-ataxia-telangiectasia mutated (p-ATM), 14-3-3 proteins sigma
(14-3-3σ), p53, MDC1, O(6)-methylguanine-DNA methyltransferase (MGMT), while up-regulating
caspase-3, -8, p-p53, p-H2AX, and cytochrome c expression [79–82,85,86]. In a rat model of leukemia,
kaempferol reduced the release of beta-hexosaminidase as a marker of degranulation in basophilic
leukemia (RBL-2H3) cells [87], and increased the accumulation of mediators and the secretory granule
development in human leukemic mast cells (HMC-1) [88].
4.8. Anti-Lung Cancer Activity
Lung cancer, such as non-small-cell lung cancer, displays a poor prognosis and is currently
contributing to increasing the number of cancer-related deaths worldwide [89]. Kaempferol
concentration dependently prevented the growth of lung adenocarcinoma A549 cells [90–93], decreased
colony formation, and triggered apoptosis [94]. Kaempferol also markedly prevented cell migration,
recovered the loss of E-cadherin, and suppressed EMT [89]. Kaempferol still downregulated the
expression of claudin-2, AKT/PI3K phosphorylation, ERK pathways, Bcl-2, Bcl-xL, MEK1/2, MMP2,
tissue inhibitor of metalloproteinases 2 (TIMP2), MAPK and up-regulated the expression of Bax,
Fas, cleaved-caspase-3,-7,-8,-9, AIF (caspase-independent), and miR-340 transcription, involved in
the apoptosis pathway [90–95]. In a lung metastasis model, kaempferol was also able to reduce the
volume of subcutaneous xenograft and the number of metastasis compared to the control group [94].
In addition, it showed a significant effect in killing cancer cells by radiation in a BALB/c nude mouse
xenograft model of A-549 cells [96].
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4.9. Anti-Kidney Cancer Activity
Renal cell carcinoma (RCC) represents the most prevalent primary kidney cancer [97]. Kaempferol
significantly inhibits cell growth and triggers apoptosis in RCC (786-O and 769-P cells) [98,99].
Kaempferol exerts its anticancer activity through preventing cell migration and invasion, inhibiting
MMP-2 protein, downregulating AKT phosphorylation, and increasing the focal adhesion kinase
(FAK) activity [97]). It also up-regulates cyclin B1 expression, PARP cleavages, and p21 expression and
promotes activation of the EGFR/p38 signaling pathway [98,99].
4.10. Anti-Bladder Cancer Activity
Bladder cancer is becoming the most common type of cancer of the urinary tract [100]. Kaempferol can
strongly and selectively inhibit bladder cancer cells by promoting cell cycle arrest and apoptosis [100–103].
Also, kaempferol acts by downregulating the PTEN/PI3K/AKT pathway, DNA methyltransferases
(DNMT3B), CDK4, CyclinD1, Mcl-1, Bid, and Bcl-xL, and upregulating p53, p38, p21, p-ATM, p-BRCA1,
DNA methylation, and Bid and Bax expression [100,102,103]. These in vitro findings were further
validated by experiments in subcutaneous xenografted mouse models. Kaempferol significantly
suppressed tumor growth as well as cancer metastasis and invasion in xenografted mice with regards to
the untreated control compared to the control group mice, and caused downregulation of growth-related
markers and c-Met/p38 signaling pathway, yet upregulated apoptosis markers [101].
4.11. Anti-Oral Cancer Activity
Oral squamous cell carcinomas (OSCC) is the sixth most prevalent cancer worldwide [104].
In in vitro studies, kaempferol displayed antiproliferative effect on pharynx (FaDu) and oral cavity
carcinoma (PCI-13) [105], human esophageal squamous carcinoma (Eca-109), and human tongue
squamous carcinoma (SCC4, SCC-1483, SCC-25, SCC-QLL1) cells, prevented clone formation and cell
migration and invasion, and induced substantial apoptosis [104,106–108]. Kaempferol also caused cell
cycle arrest at G0/G1 phase and downregulated Bcl-2, MMP-2, c-Jun, and hexokinase-2 expression.
Kaempferol also increased glucose uptake, EGFR activation, ERK1/2 phosphorylation, and upregulated
Bax, cleaved caspase-3, -9, and PARP [104,106–108]. Finally, the anticancer potency of kaempferol was
further confirmed in a mice xenograft model, revealing the ability to significantly prevent the growth
of tumor size coupled with a marked decrease in hexokinase-2 expression and EGFR activity in tumor
tissues [107].
4.12. Anti-Bone Cancer Activity
Kaempferol dose-dependently inhibits the growth of human osteosarcoma cells U-2 OS, 143B,
and HOB cells and the migration of human U-2 osteosarcoma (OS) cells with poor toxicity on
hFOB cells, a human fetal osteoblast progenitor [109,110]. Kaempferol acts by downregulating the
AP-1 DNA binding activity, MMP-2, -9, and urokinase plasminogen activator (uPA) that, in turn,
reduces phosphorylated p38, ERK, and JNK [110]. In BALB/c(nu/nu) mice inoculated with human
osteosarcoma cells (U-2 OS), kaempferol significantly decreased the number of viable cells and reduced
the tumor size [109]. The in vivo anti-bone cancer effects of kaempferol have also been demonstrated
in BALB/c(nu/nu) mice inoculated with U-2 OS cells [109].
4.13. Anti-Cervical Cancer Activity
Kaempferol was found to selectively prevent the growth of human cervical cancers cells, such as
HeLa, multidrug-resistant human cervical carcinoma, KB-V1, and SiHa cells with regards to the normal
cells and HFF cells [111–114]. Kaempferol also caused cell cycle arrest at the G2/M phase and apoptosis,
correlated with downregulation of PI3K/AKT and human telomerase reverse transcriptase (hTERT)
pathways, Pgp, Rh123 efflux, cyclin B1, NF-κB nuclear translocation, CDK1, Bcl-2, and upregulation of
p53 with mitochondrial membrane potential disruption [111–115].
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4.14. Anti-Stomach Cancer Activity
Experimental studies on stomach cancer revealed the antiproliferative activity of kaempferol on
human gastric cancer cells (MKN28 and SGC7901) by promoting autophagy, cell cycle arrest at G2/M
phase, and cell death [116,117]. The induced autophagic cell death was linked to the upregulation
of Bax, cleaved caspase-3, -9, cleaved PARP, IRE1-JNK-CHOP signaling, and downregulation of p62,
cyclin B1, Cdc25C, Bcl-2, CDK1, p-AKT, cyclooxygenase 2 (COX-2), and p-ERK expression [116,117].
4.15. Anti-Ovarian Cancer Activity
Experiments using human ovarian cancer cell lines (A2780/CP70, A2780/wt, SKOV-3, OVCAR-3)
showed that kaempferol could inhibit tumor growth, proliferation, and angiogenesis by decreasing
vascular endothelial growth factor (VEGF) expression [118]. Kaempferol also induces apoptosis
and cell cycle arrest at G2/M phase via upregulation of Chk2/Cdc25C/Cdc2, DR5, DR4, JNK, CHOP,
p38, p21, ERK1/2 proteins, caspase-3, -7, -8, Bad, Bax, and p53 proteins, with downregulation of
hypoxia-inducible factor 1α (HIF-1α), a regulator of VEGF expression [118–123].
Table 1. Studies of anticancer activities of kaempferol in vitro.
Cancer Types Mechanisms of Action Cancer Cells Lines Origin of Cells References
Bladder
Downregulation: phosphorylated AKT
(p-AKT), Cyclin D1, CDK4, Bid, Mcl-1 and
Bcl-xL in human cells; DNMT3B expression
in mouse cells
Upregulation: p38, p53, p21, p-BRCA1,
p-ATM, Bid, Bax expression in human cells;
DNA methylation in mouse cells
SV-HUC-1 (human),
T24 and 5637
(mouse)
Human, Mouse [100,124]
Blood
Downregulation: p-ATM,
phosphate-ataxia-telangiectasia, AKT, BCL2,
ABCB1, and ABCC1 expression
Upregulation: CASP3 and BAX/BCL-2
expression, subG1 population, Rad3-related
(p-ATR), 14-3-3 proteins sigma (14-3-3σ),
DNA-dependent serine, MDC1 protein, p53
and p-H2AX expression
HL-60, NB4 Human [79,80]
Bone
Downregulation: migration, MMP-2, MMP-9,
and uPA expression, ERK, p38, and JNK
phosphorylation and DNA binding activity
of AP-1, endoplasmic reticulum stress and
mitochondrial signaling pathways
U-2 OS, HOB, 143B Human [109,110]
Brain
Apoptosis Downregulation: phosphorylation
of ERK, AKT, anti-apoptotic proteins XIAP
and survivin expression, depolarization of
mitochondrial membrane potential
Upregulation: caspase-3 activity
C6, A172 Rats, Human [55,57]
Breast
Downregulation: Bcl2, E2, EMT-markers
(N-cadherin, E-cadherin, Slug, and Snail),
cathepsin D, cyclin D1, cyclin E, pAkt,
pMEK1/2, pIRS-1, RhoA and Rac1 activation
of ER/PR-silence and HER2-silence SK-BR-3
Upregulation: p21, bax γH2AX, cleaved
caspase-3&-9, and p-ATM
Suppression of migration and invasion
Apoptosis, cell cycle arrest at G2/M and DNA
damage, reduced cell migration and
invasion ability
Triple-negative BC
(TNBC) cell
MDA-MB-231,
MCF-7
Human [10,41,42,47,51,60]
Cervical
Downregulation: PI3K/AKT and
hTERT pathways
Upregulation: mitochondrial membrane
potential disruption, intracellular free
calcium elevation Apoptosis
HeLa, SiHa Human [111,112,114]
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Cancer Types Mechanisms of Action Cancer Cells Lines Origin of Cells References
Colon
Downregulation: CDK2, CDK4, cyclins D1,
cyclin B1, cyclin E, cyclin A, Cdc25C, Cdc2,
IGF-I&-II secretion, heregulin (HRG)-β
expression and HRG-β-induced
phosphorylation of the AKT, ERK-1/2, IGF-IR,
and ErbB3
Upregulation: caspase-3,-8,-9, p21, p53,
phospho-p38 MAPK and enhanced the PARP
cleavages, JAK/STAT3, MAPK, PI3K/AKT,
and NF-κB expression
Blocked ROS generation, cell cycle arrest at
G1 and G2/M arrest, and cell migration
LS174, HCT15,
HCT116, SW480,
HT-29
Human [64–66,125]
Kidney Downregulation: MMP-2, AKTphosphorylation and FAK 786-O Human [97]
Liver
Downregulation: mitochondrial membrane
potential, mitochondrial swelling, SOCS3,
STAT3, miR-21, PI3K/AKT/mTOR signaling
pathway Upregulation: PTEN, caspase-3,
JAK1, Tyk2, STAT1/2, endogenous
IFN-α-regulated genes expression
Hepatoma HepG2 Rat, Human [59,60,63]
Lung
Downregulation: AKT/PI3K and ERK
pathways, TIMP2, and MMP2
phosphorylation, Bcl-2, cyclin D1,
claudin-2 expression
Inhibited STAT3 factor binding
Upregulation: PTEN, Bax, miR-340, Fas,
cleaved-caspases 3, 8, and 9,
and cleaved-PARP
Apoptosis, cell cycle arrest at G2/M, prevent
migration and invasion
A549, HCCC9810,
QBC939 Human, mice [90,92,94,96]
Oral
Suppress migration and invasion
Downregulation: MMP-2, TIMP-2 mRNA,
c-Jun activity, ERK1/2 phosphorylation
SCC4 Human [104]
Ovarian
Upregulation: DR4, DR5, p53, p38, ERK1/2,
CHOP, JNK, death
receptors/FADD/Caspase-8 pathway
Downregulation: anti-apoptotic proteins
A2780/CP70,
OVCAR-3, SKOV-3 Human [119–121]
Pancreatic
Downregulation: EGFR-related AKT, Src,
and ERK1/2, pathways
Upregulation: suppressive function of
regulatory T cells (Tregs), FOXP3 expression
Block cell migration
Miapaca-2, Panc-1,
SNU-213, Treg cells Human, Rats [76,77]
Prostate
Downregulation: androgen receptor
expression
Upregulation: caspase-8, -9, -3 and poly
(ADP-ribose) polymerase proteins cleavage
C4-2, LNCaP Mice, Human [72,74]
Stomach
Induce significant apoptosis and cell cycle
arrest at G2/M
Downregulation: COX-2, Bcl-2 p-ERK,
p-AKT expression
Upregulation: Bax, cleaved caspase-3 and -9
MKN28 and
SGC7901 Human [116]
5. Conclusions
Cancer accounts among the most overbearing human health problems, relying on chemoprevention
approaches as a way to diminish both incidence and mortality. The scrutiny of kaempferol extraordinary
list of cancer-fighting properties highlights its full potential. These studies are promising, especially
because kaempferol selectively inhibits cancerous cells without affecting healthy ones. In vitro
studies unveiled the broad spectrum of kaempferol anticancer targets, including apoptosis, metastasis,
inflammation, and angiogenesis. Therefore, cancer cells that often adapt to VEGF inhibition, following
treatment with kaempferol, may not escape other detrimental actions induced by this natural flavonoid.
Even though kaempferol is questionable as a cancer treatment, it seems to constitute an interesting
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option when it comes to safety. However, data on the long-term effect of kaempferol intake are scarce.
Though kaempferol poor bioavailability represents a significant obstacle, the use of kaempferol-based
nanoparticles has brought more hope on cancer chemoprevention strategies. Moreover, most of the
research conducted on kaempferol anticancer potency was in vitro, making it difficult to draw a final
conclusion on its usefulness. In vivo studies and clinical trials using an exact dose of kaempferol are
scarce so far, thus stressing the need for more in-depth experiments varying the dose of kaempferol
alone as well as using it with other flavonoids. These data will be of utmost interest to apprehend on
kaempferol efficacy in the context of cancer.
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